Here’s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks

EyePoint, Inc. (NASDAQ:EYPT) is among the best get rich quick stocks to buy right now. Andreas Argyrides, an analyst at Chardan, significantly lifted the price target on EyePoint, Inc. (NASDAQ:EYPT) to $65 from $29 on July 1. Calling the company “a de-risked, single-asset, catalyst-rich story,” the firm maintained a Buy rating on the shares following a transfer of coverage.

The firm expects readouts from Phase 3 studies of DURAVYU in wet AMD, scheduled for August and October 2026, to be the key catalysts. The two biggest retinal markets, wet AMD and DME, are anticipated to achieve $13 billion in U.S. sales next year, the firm said.

science, laboratory, bioscience

Phovoir/Shutterstock.com

In one year, EyePoint, Inc. (NASDAQ:EYPT) has returned twice as much as the market, with nearly 25% outperformance. Overall, the company has a Buy rating from all twelve analysts covering the stock. With an upside potential of 153.93% based on the one-year median price target of $35.50, EYPT is among the best get rich quick stocks to buy right now.

EyePoint, Inc. (NASDAQ:EYPT) is a Massachusetts-based company specializing in therapeutics for people living with serious retinal diseases. The company’s pipeline is built on its proprietary bioerodible Durasert E technology.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.